NCT00004731

Brief Summary

The purpose of this study is to compare the effects of varying dosage of coenzyme Q10 (CoQ10) versus a placebo in the treatment of Parkinson's disease (PD) in patients with early, untreated PD.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Timeline
Completed

Started Sep 1998

Longer than P75 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 1998

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

February 25, 2000

Completed
3 days until next milestone

First Posted

Study publicly available on registry

February 28, 2000

Completed
3.6 years until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2003

Completed
Last Updated

June 24, 2005

Status Verified

December 1, 2003

First QC Date

February 25, 2000

Last Update Submit

June 23, 2005

Conditions

Parkinson's Disease

Keywords

Parkinson's diseasecoenzyme Q10

Interventions

Coenzyme Q10DRUG

Eligibility Criteria

Age30 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • The subjects must have the three cardinal features of PD: slowness of movement, resting tremor and rigidity. The signs of PD must be greater on one side.

You may not qualify if:

  • Disorders that mimic PD.
  • Other serious medical problems.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Rochester

Rochester, New York, 14620, United States

Location

MeSH Terms

Conditions

Parkinson Disease

Interventions

coenzyme Q10

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Study Officials

  • Clifford W. Shults, M.D.

    University of California, San Diego

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
NIH

Study Record Dates

First Submitted

February 25, 2000

First Posted

February 28, 2000

Study Start

September 1, 1998

Study Completion

October 1, 2003

Last Updated

June 24, 2005

Record last verified: 2003-12

Locations

US(1)